New Releases from NCBI BookshelfBimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal).Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal).By admin / March 11, 2025 Post Content
